|
Originally published In Press as doi:10.1194/jlr.M400437-JLR200 on December 16, 2004
Journal of Lipid Research, Vol. 46, 564-571, March 2005
Copyright © 2005 by American Society for Biochemistry and Molecular Biology
APOA5 polymorphisms influence plasma triglycerides in young, healthy African Americans and whites of the CARDIA Study
Kathy L. E. Klos1,*,
Sara Hamon ,
Andrew G. Clark ,
Eric Boerwinkle*,
Kiang Liu** and
Charles F. Sing
* Human Genetics Center, University of Texas Health Science Center, Houston, TX
Department of Human Genetics, University of Michigan, Ann Arbor, MI
Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY
** Department of Preventive Medicine, Northwestern University, Chicago, IL
1 To whom correspondence should be addressed. e-mail: kklos{at}sph.uth.tmc.edu
Genetic variation in the apolipoprotein A-V gene (APOA5) has been associated with variation in plasma triglyceride (TG) levels in African American and white females and males older than 40 years and/or at increased risk of coronary artery disease. We have examined whether plasma TG levels are associated with 16 APOA5 polymorphisms in young (1830 years) African American (1,075 females and 783 males) and white (1,041 females and 932 males) individuals of the Coronary Artery Risk Development in Young Adults (CARDIA) Study selected without regard to health. Plasma TG was significantly (P < 0.01) associated with markers 27376 and 28837 (3A/G) in both white females and males, with 27709 (1131T/C) and 29085 in white males, with 29009 (S19W) in African American females and white males, and with 30966 in African American females. No statistically significant associations were observed in African American males. These six single-nucleotide polymorphisms individually accounted for 00.78% of lnTG variation among white females, 02.46% among white males, and 00.69% among African American females.
The results of our study suggest a small but replicable context-dependent influence of the APOA5 gene region on plasma TG levels in young, healthy individuals.
Supplementary key words apolipoprotein AV haplotypes SNP association coronary artery disease genetics human

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y Yamada, S Ichihara, K Kato, T Yoshida, K Yokoi, H Matsuo, S Watanabe, N Metoki, H Yoshida, K Satoh, et al.
Genetic risk for metabolic syndrome: examination of candidate gene polymorphisms related to lipid metabolism in Japanese people
J. Med. Genet.,
January 1, 2008;
45(1):
22 - 28.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Qu, G. Perdomo, D. Su, F. M. D'Souza, N. S. Shachter, and H. H. Dong
Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice
J. Lipid Res.,
July 1, 2007;
48(7):
1476 - 1487.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Moreno-Luna, F. Perez-Jimenez, C. Marin, P. Perez-Martinez, P. Gomez, Y. Jimenez-Gomez, J. Delgado-Lista, J. A. Moreno, T. Tanaka, J. M. Ordovas, et al.
Two Independent Apolipoprotein A5 Haplotypes Modulate Postprandial Lipoprotein Metabolism in a Healthy Caucasian Population
J. Clin. Endocrinol. Metab.,
June 1, 2007;
92(6):
2280 - 2285.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Albrechtsen, S. Castella, G. Andersen, T. Hansen, O. Pedersen, and R. Nielsen
A Bayesian Multilocus Association Method: Allowing for Higher-Order Interaction in Association Studies
Genetics,
June 1, 2007;
176(2):
1197 - 1208.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L.E. Klos, C. F. Sing, E. Boerwinkle, S. C. Hamon, T. J. Rea, A. Clark, M. Fornage, and J. E. Hixson
Consistent Effects of Genes Involved in Reverse Cholesterol Transport on Plasma Lipid and Apolipoprotein Levels in CARDIA Participants
Arterioscler. Thromb. Vasc. Biol.,
August 1, 2006;
26(8):
1828 - 1836.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. E. Alborn, M. G. Johnson, M. J. Prince, and R. J. Konrad
Definitive N-terminal protein sequence and further characterization of the novel apolipoprotein a5 in human serum.
Clin. Chem.,
March 1, 2006;
52(3):
514 - 517.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Hodoglugil, S. Tanyolac, D. W. Williamson, Y. Huang, and R. W. Mahley
Apolipoprotein A-V: a potential modulator of plasma triglyceride levels in Turks
J. Lipid Res.,
January 1, 2006;
47(1):
144 - 153.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. E. Schultze, W. E. Alborn, R. K. Newton, and R. J. Konrad
Administration of a PPAR{alpha} agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio
J. Lipid Res.,
August 1, 2005;
46(8):
1591 - 1595.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|